Leland S. Hu1,2, Seban Liu3, Dilini
S. Pinnaduwage4, Kris A. Smith5, Peter Nakaji5,
Amylou C. Dueck6, Todd Jensen7, Jennifer M. Eschbacher8,
Joseph E. Heiserman2, John P. Karis2, Josef Debbins3,
Burt G. Feuerstein9, Kathleen M. Schmainda10, Leslie C.
Baxter3
1Radiology, Mayo Clinic, Arizona,
Scottsdale, AZ, United States; 2Radiology, Neuroradiology Section,
St. Joseph's Hospital - Barrow Neurological Institute, Phoenix, AZ, United
States; 3Keller Center for Imaging Innovation, St. Joseph's
Hospital - Barrow Neurological Institute, Phoenix, AZ, United States; 4Radiation
Oncology, University of California - San Francisco, San Francisco, CA, United
States; 5Neurosurgery, St. Joseph's Hosptial - Barrow Neurological
Institute, Phoenix, AZ, United States; 6Biostatistics, Mayo
Clinic, Arizona, Scottsdale, AZ, United States; 7Imaging
Biometrics, LLC; 8Neuropathology, St. Joseph's Hospital - Barrow
Neurological Institute, Phoenix, AZ, United States; 9Neuro-Oncology,
St. Joseph's Hospital - Barrow Neurological Institute, Phoenix, AZ, United
States; 10Radiology, Medical College of Wisconsin, Milwaukee, WI,
United States
We
present methods to calculate Perfusion MRI (pMRI) fractional tumor bulk,
which quantifies and spatially localizes areas of tumor recurrence within
non-specific contrast enhanced (CE) MRI lesions. We correlate these measures with the
percentage, or fraction, of tissue samples histopathologically diagnosed as
tumor, in a group of recurrent Glioblastoma Multiforme (GBM) patients
undergoing multiple stereotactic biopsies.